Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

BioVaxys Technology Corp. C.BIOV

Alternate Symbol(s):  BVAXF

BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.


CSE:BIOV - Post by User

Post by javaman12on Nov 14, 2024 5:52pm
60 Views
Post# 36313759

New Idea For The Company!

New Idea For The Company!We all know how the Avian flu has been costing farmers significant losses as they have been forced to destroy any infected poulty or cattle, etc, to help prevent any spread of disease to other nearby facilities.

An animal plague like this can get out of control very quickly! So the regulatory authorities have to crack down and euthanize any effected animals. That means all animals on a farm have to be slaughtered right away! That is a very costly remedy to prevent the spread of a very virulent disease!

What if a biotech company might develop and patent a drug to give a one shot vaccination to all farm yard animals. It wouldn't have to be an expensive development project for BioVaxys to do since no costly human trials would need to be done! 

Imagine if BioVaxys could beat Zoetis at their very own game with a good patented idea and with a good, one shot deal like their DPX delivery platform to prevent any such problem from even occuring! Maybe Zoetis might like to take out a license or partner with BioVaxys in some form of lucretive commercial vaccine production?

Of course, every farmer would want to vaccinate all of his animals right away to avoid any unnecessary loss.

And you could bet that any insurance company providing loss insurance would make vaccination an absolute requirement for their basic coverage once a preventive measure like this became available. 

I contacted BioVaxys about this idea and hope that they might get back to me or at least consider this idea as a good marketing opportunity! It seems to me that it might be worthy of a cost and market analysis to see if it is really a feasible idea! They are the experts who know better than me!

I also asked them how their procurement of the DPX lipids from Dalhousie University is going. I mentioned that it seems to be taking some time to get all of these negotiations finalized. I suggested that if money is the main stumbling block that the company might consider a share swap deal to finance much of the package that BioVaxys needs including the laboratory space and equipment that they might provide!

Cash and shares made the IVM intellectual property deal happen for the company! 

Good cooperation between the company and the University of Dalhousie would be a real coup for both parties in their developmental investigations in the Biotech field.

It would give the university a good industry connection with a early stage company already having many good patents in the field that needs many more work skilled workers to fully develop!

What better opportunity would there be for masters and doctorate students to excel by becoming more proficient in their studies as they prepare to enter their biotech field in industry or continue in the related fields of academia?

These are just a few ideas from a shareholder's perspective.  But thinking harder is what junior companies must do to compete with the big players, more effectively!

 And we shareholders do want our company managers to make the best of decisions. 

Why not pursue the human allergen as well as the animal Avian flu market at the very same time?

A lot of university students and faculty could add a lot of help if they were well incentivized to make this happen! Shares in a start up company might make them work, even harder, to achieve these goals!

Bird flu now spreads quickly across the species barrier. It has even recently touched the human population. Why might this be?

                                        Mutation is an enemy that we all need to fight!

                                  Once the remedy becomes available, get those shots!

                                                    We are all in this together!

                                                           All the best! Java

 
<< Previous
Bullboard Posts
Next >>